To review systematically the published literature regarding the impact of treatment for OSA on monetized health economic outcomes.
OSA is a serious and highly prevalent medical condition with well-documented adverse health consequences. In the United States, approximately 14% of men and 5% of women between the ages of 30 and 70 years have moderate to severe OSA, 1 and the prevalence of the disorder is increasing. 2, 3 Relative to healthy control subjects, patients with OSA have numerous adverse health consequences, including increased risk for cardiovascular disease, [4] [5] [6] stroke, 7 metabolic syndrome, 8, 9 reduced quality of life, 10 and premature death. 11, 12 In addition to these health-related outcomes, OSA is associated with significant economic costs borne by multiple stakeholders, including patients, payers, employers, and society. 13 A white paper commissioned by the American Academy of Sleep Medicine estimated the total societal-level costs of OSA to exceed $150 billion per year in the United States alone, including $86.9 billion because of lost workplace productivity, $30 billion because of increased health-care use (HCU), $26.2 billion because of motor vehicle crashes (MVCs), and $6.5 billion because of workplace accidents and injuries. 14 Despite consensus that OSA causes substantial economic burden, far less is known about the potential economic benefit of OSA treatment. In the modern health-care climate of rising costs on the one hand and limited resources on the other, such knowledge is required by payers and policy makers to guide evidence-based decision-making regarding allocation of scarce health-care resources. It is thus somewhat surprising that few studies have sought to aggregate extant data or assess the state of the science regarding the health economic impact of OSA treatment (eg, Leger et al 15 and Tarasiuk and Reuveni 16 ). Reviews to date have primarily focused on the costs of untreated OSA (eg, Leger et al 15 and Tarasiuk and   Reuveni   16 ), and a representative literature review included only five studies examining the impact of treatments on HCU. 16 To address this important gap in knowledge, we systematically reviewed the literature of cost-effectiveness and monetized economic impact of OSA treatments. Specifically, this systematic review sought to answer the question, "What is the impact of OSA treatment on monetized health economic outcomes?"
Materials and Methods
This study adheres to reporting requirements as outlined in the Preferred Reporting Items for Systematic Reviews and Meta-Analyses statement. 17 To our knowledge, the research protocol is published here for the first time and was not previously registered elsewhere.
Throughout the article, financial costs are adjusted for inflation and presented in 2017 US dollars (USD), with the originally published costs in parentheses. Results originally published in USD were adjusted for inflation by using an online calculator from the Bureau of Labor Statistics (http://www.bls.gov/data/inflation_calculator.htm). Results originally published in non-US currencies were first converted to USD for the publication year by using an online calculator (http://www.oanda.com/currency/converter/) and then adjusted for inflation.
Inclusion Criteria
Empirical studies that employed observational or experimental designs and provided monetized health economic outcomes of OSA treatments based on comparisons with no treatment were eligible for this systematic review. Inclusion criteria for individual studies were as follows: (1) scientific publication in the English language, (2) patients with OSA, (3) patients in whom OSA was treated, (4) comparator group with OSA diagnosis but no OSA treatment, and (5) health economic outcome expressed in monetary units. Exclusion criteria included conference abstracts or proceedings, single case studies, economic modeling studies based on previously published data, and reviews.
Health Economic Outcomes
On the basis of prior literature, several domains of health economic outcome were identified and included in this systematic review, including HCU, costs, workplace productivity, accident risk, and quality-adjusted life years (QALYs). In the broader medical literature, health economic outcomes are often secondary end points in clinical studies, and this was the case in the current systematic review. Given the purpose of this review, our focus was to analyze the impact of OSA treatments on monetized health economic outcomes.
Information Sources
A health sciences librarian (A. G. S.) conducted structured searches of major research databases: PubMed, Embase (Embase.com), and the Cochrane Central Register of Controlled Trials (Wiley).
Data Searches
Searches required at least one term to be present from three core concepts: (1) health economics, (2) sleep apnea, and (3) treatment (eg, terms such as "positive airway pressure," [PAP] "oral appliance," [OA] and "surgery"). These searches were completed on December 7, 2016, and updated on September 18, 2017. Search strategies used both Medical Subject Headings and text words and were customized to each database (Table 1) . In addition to the database searches, reference lists of eligible articles were reviewed.
Study Selection
To identify studies for full-text review, titles and abstracts were independently rated by at least two reviewers. In the case of disagreement, the title and abstract were rated by at least one additional reviewer, and disagreement was resolved through discussion and consensus. Next, studies selected for full-text review were assessed in detail by at least two reviewers.
Data Collection Process
Data were extracted from reports and reviewed for accuracy by a minimum of two reviewers using a standardized extraction template.
Data Items
Depending on the study design, information extracted included (1) study sample or base case; (2) study design; (3) perspective; (4) follow-up duration; (5) OSA diagnostic criteria; (6) OSA treatment and adherence information, when available; (7) health economic outcomes; (8) and key health economic results. A detailed summary of extracted information is included in e- Table 1 .
Risk of Bias in Individual Studies
Risk of bias for randomized controlled trials (RCTs) was assessed using the Cochrane risk-of-bias tool based on random sequence generation, allocation concealment, blinding of participants and personnel, blinding of outcome assessors, selective outcome reporting, and incomplete outcome data and other sources of bias. On the basis of the assessment of each domain, risk of bias was judged as high, unclear, or low. 18 The methodological quality of included observational studies was assessed using the Newcastle-Ottawa Scale (NOS) for nonrandomized trials. 19 The NOS assesses risk of bias in casecontrol and cohort studies in eight domains, which are broadly categorized into study group selection, comparability, and ascertainment of either the exposure or outcome for case-control or cohort studies, respectively. 19 On the basis of the NOS, each study was scored as being at low risk of bias (studies receiving eight stars), unclear risk of bias (studies receiving seven stars), or high risk of bias (studies receiving fewer than seven stars).
Synthesis of Results
Data from included studies were aggregated and synthesized qualitatively. Data were evaluated for meta-analysis by assessing studies for clinical, geographic, and methodological consistency. On the basis of published guidelines, excessive statistical heterogeneity (ie, defined as I 2 $ 70%
20
) rendered a planned meta-analysis inappropriate. (Fig 1) .
Study Characteristics
Study Design: The most common study design was a retrospective cohort study, which was employed in 10 studies. [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] Three studies employed RCT designs, [31] [32] [33] and one study employed a quasi-experimental design. 34 Other designs included two case-control studies 35, 36 and a prospective cohort study. 37 Three studies included populations with comorbid conditions, including type 2 diabetes mellitus, 35 sickle cell disease (SCD), 29 and heart failure (HF). 25 Tables 2 and 3 summarize key characteristics of included experimental and observational studies, respectively.
Methodological Quality and Risk of Bias:
The methodological quality of the three included RCTs was generally high, and all RCTs showed low risk of bias in most of the Cochrane risk-of-bias domains. One RCT was open label, so blinding of participants and study personnel was absent. 33 In another, blinding of participants and study personnel was unclear. 32 Allocation concealment was not reported in two RCTs. 32, 33 On the basis of the NOS, risk of bias across all included observational studies was low. Six studies, including five cohort studies 21, 23, 25, 26, 29 and one case-control study 35 scored nine stars and were deemed to have low risk of bias. Seven other cohort studies did not adjust for important covariates; thus, risk of bias was deemed unclear, and these studies were scored seven stars. 22, 24, 27, 30, 34, 36, 37 A final cohort study 28 did not clarify representativeness of the sample and was also scored seven stars.
Participants: As presented in Tables 2 through 5 Kingdom (n ¼ 3), 31, 33, 35 Canada (n ¼ 4), 21, 22, 28, 37 and one each from Denmark, 26 Finland, 34 France, 32 Israel, 36 Spain, 30 and Sweden. 27 Although one study each included all-male 21 and all-female 22 samples, most empirical studies were sex-mixed and included > 70% male participants. The majority of studies included middle-aged adults, with two studies focusing on older adults 25, 31 and two studies including children < 20 years of age. 26, 36 Perspective: All seven cost-effectiveness analysis (CEA) or cost-utility analysis (CUA) studies reported results from the perspective of the payer.
Follow-up Duration: Follow-ups ranged from 6 weeks 33 to 5 years, 21, 35 with most studies having follow-ups of 6 months to 2 years.
OSA Diagnostic Criteria: OSA diagnoses varied by study setting. In clinic-based studies, OSA was diagnosed during overnight polysomnography (PSG; n ¼ 9), 21, 22, 27, 28, 32, 33, 36, 37, 38 home sleep apnea testing (HSAT; n ¼ 1), 31 or mixed approaches such as HSAT followed by PSG if necessary (n ¼ 2). 30, 34 In administrative review studies, OSA diagnosis was operationalized by diagnostic, procedural, or equipment-related codes indicative of OSA (n ¼ 6). [23] [24] [25] [26] 29, 35 OSA Treatments: In the vast majority of studies, the OSA treatment was PAP, including CPAP, autoadjusting PAP, and bilevel PAP. PAP adherence was reported in all but five studies, [23] [24] [25] 28, 39 with a roughly equal number of studies employing objective (eg, machine counter or Secure Digital download) [30] [31] [32] [33] [34] and subjective (eg, patient or bed-partner report) 21, 22, 27, 35, 37 measures of adherence. Other treatment modalities included surgical approaches (n ¼ 3) 26, 29, 36 and OAs (n ¼ 1). 33 Health Economic Outcomes: The most common economic outcome was HCU (n ¼ 17). Some studies included measures of health-related quality of life (HrQOL; ie, QALYs) and CEA or CUA (n ¼ 7), 28, [30] [31] [32] [33] [34] [35] accident and injury-related costs (n ¼ 3), [30] [31] [32] and measures of lost workplace productivity such as costs of days missed from work and costs of short-term disability (n ¼ 3). 24, 26, 30 Results of Individual Studies Table 2 (with additional detail presented in e- Table 1 ).
Impact of OSA Treatment on HCU: Eight observational studies evaluated the impact of PAP therapies alone on HCU expressed in USD. [21] [22] [23] [24] [25] [26] [27] 37 Seven of eight studies found that, compared with no treatment, PAP was associated with reduced HCU and costs. Conversely, Jennum and Kjellberg 26 conducted a large administrative review in Denmark and found that relative to 1 year prior to diagnosis, neither CPAP nor uvulopalatopharyngoplasty (UPPP) was associated with reductions in HCU within 2 years.
In addition, three observational studies evaluated the impact of OSA surgeries on HCU 26, 29, 36 : Two evaluated the economic impact of surgical approaches for OSA among children and adolescents and one among adults. One of the two studies conducted among children involved children with SCD, and both studies found that, compared with no treatment, adenotonsillectomy was associated with reductions in total cost, hospitalizations, and ED visits, as well as fewer outpatient visits among those with SCD. A third study evaluated UPPP among adults with OSA and found no benefit from UPPP on HCU or costs. 26 Results are presented in Table 3 (with additional detail presented in e- Table 1 ).
Impact of OSA Treatment on Workplace Productivity and Absenteeism: Three studies 24, 26, 30 evaluated the impact of OSA treatment on workplace productivity and days missed from work. In a casecrossover study, Català and colleagues 30 found that relative to 1 year prior to treatment, CPAP was associated with a significant reduction in days missed from work at 1-year follow-up (7.5 vs 4.2 days missed; P < .001). Notably, reductions in days missed were greater among PAP adherers than among nonadherers (P < .001), who demonstrated a significant increase in days missed from baseline to 1 year follow-up (5.2 vs 20.8 days missed; P < .001). 30 In a cohort study sought to include work accidents, home accidents, and MVCs in estimates of OSA costs. However, no such accidents were reported during the 6-month follow-up, so differences between groups could not be evaluated. 32 Results are presented in Table 5 (with additional detail presented in e- Table 1 ).
Synthesis of Results
As detailed previously and presented throughout Tables 2 through 5 , there was substantial betweenstudy heterogeneity in most key study characteristics.
In particular, studies varied widely in their assessment of economic outcomes: HCU, total costs, and number of days missed from work were not defined consistently across studies. Even when studies were stratified by geographic region, betweenstudy variability presented substantial challenges to pooling outcomes. For example, when we attempted In addition to these contraindications to the quantitative combining of results, the studies were conducted in many different countries and were designed to address questions of relevance to those localized health systems. Thus, any final pooled estimate would not reflect the economic realities of any one country and would be of limited value for informing health-care service planning and resource allocation decisions globally. In most cases, such policy-level decisions are highly specific to location, country, and system, and meta-analytic approaches are often inappropriate. [40] [41] [42] Given these practical barriers and theoretical contraindications for a quantitative analysis, qualitative synthesis was employed to aggregate results of individual studies included in this systematic review.
In total, 17 separate studies tested 18 OSA treatments.
Thirteen studies compared PAP with no treatment, standard care, or lifestyle and weight-loss counseling, and one study tested immediate PAP with delayed PAP. 32 Among non-PAP studies, the most common comparator was no treatment, including studies of surgical approaches (n ¼ 3) 26, 29, 36 and OAs. 33 Overall, 15 of 18 OSA treatments were associated with a positive health economic outcome. In terms of specific treatment modalities, CPAP was associated with a positive health economic outcome in 12 of 14 studies, with some positive findings being limited to specific subpopulations (ie, only patients with severe OSA 32 ).
OAs were associated with a positive health economic outcome in one study. 33 Surgical approaches were associated with a positive health economic outcome in two studies 29, 36 and related to a negative economic outcome in one study. 26 Four studies found PAP adherence to enhance economic outcomes, 22, 27, 30, 37 and one study detected no relationship between adherence and outcomes. 34 
Discussion
Based on this comprehensive systematic review of the literature, the overwhelming majority of evidence supports the beneficial economic impact of OSA treatments. Studies to date have been conducted in North America, Europe, and Israel and employed a wide range of research methodologies, including retrospective and prospective cohort designs, case-control designs, and CEAs nested within RCTs. Irrespective of study design, PAP was the most frequently studied OSA therapy. Nearly all comparisons found that relative to no treatment, PAP was associated with favorable economic outcomes, including increased cost-effectiveness, reduced HCU, and improved workplace productivity and reduced days missed from work. OA and surgical approaches were less frequently studied, and results were somewhat more equivocal when compared with results with PAP. Non-PAP therapies might also be cost-effective, but extant data are scant; future studies are clearly warranted.
Using standardized methodologies, we consistently found OSA treatments to be cost-effective from the Another possible explanation for the surprising finding is that the study might have been underpowered to detect effects of PAP in this sample. In addition, treatment was assigned based on clinical judgment rather than randomization, and the potential impact on results was not assessed. Despite the findings of the quasi-experimental study of the study by Lojander and colleagues, 34 the preponderance of evidence suggests that, compared with no treatment, CPAP is costeffective, especially among patients with moderate to severe OSA.
In addition to PAP, OA therapy was cost-effective. In a single RCT among patients with mild to moderate OSA, Quinnell and colleagues 33 found that relative to no treatment, self-molded, semibespoke, and fully bespoke mandibular advancement devices were cost-effective over a 6-week time frame. Semibespoke devices were the most cost-effective and suggested by the authors as a first treatment option. Although this single study requires replication with diverse OSA samples and longer follow-ups, it is highly promising that OA therapy can provide economic in addition to clinical benefit. Dental sleep medicine is a rapidly expanding domain of sleep medicine. OAs are preferred by many patients and are an accepted treatment alternative for patients with mild to moderate OSA or who are unable to tolerate PAP. 45 In addition to the CEAs, the vast majority of studies found OSA treatments to reduce HCU. Specifically, relative to no treatment, seven of eight comparisons of PAP and two of three comparisons of OSA surgeries found treatment to reduce outpatient visits, hospitalizations, ED visits, and costs. Samples included adults and children, for whom adenotonsillectomy is considered first-line treatment for OSA, as well as populations with comorbid conditions, including HF and SCD. Null findings regarding the impact of PAP and surgery on HCU were both reported in the same study, a large administrative review study conducted by Jennum and Kjellberg. 26 Three possible explanations for these null findings seem likely. First, no efforts were made to quantify or confirm PAP adherence, an inherent challenge to an administrative review methodology. Second, UPPP is an expensive procedure that does not reliably normalize the apnea-hypopnea index. 46 Finally, the 2-year time frame might have been insufficient to detect beneficial economic effect. In the current review, longer follow-ups were typically associated with more favorable economic outcomes. The authors briefly mentioned a subgroup analysis in which CPAP was associated with reduced costs during year 2, although costs remained higher than before diagnosis. However, these results were not formally reported and thus could not be assessed in detail. In summary, nine of 10 comparisons found OSA treatments to reduce HCU across the continents, ages, and populations with comorbid conditions evaluated. The findings regarding cost-effectiveness of OSA treatments and impact on HrQOL will be of particular interest to payers and policy makers charged with allocation of scarce health-care resources.
Studies also assessed the economic impact of OSA treatment on outcomes that matter to employers. Both Hoffman and colleagues 24 and Català and colleagues 30 found that, relative to 1 year prior to treatment, PAP was associated with reduced absenteeism over 2 years. Furthermore, Hoffman and colleagues 24 found that PAP was associated with reduced HCU and reduced short-term disability costs among a self-insured employee population of commercial truck drivers. These data speak directly to the needs of employers concerned with improving workplace productivity and reducing health-care spending as means to enhance business performance. 13, 47 Although Jennum and Kjellberg 26 detected no economic benefit from CPAP or UPPP, the dependent measure of labor market income was not measured directly. Furthermore, in light of the pattern of results in the study by Jennum and Kjellberg, 26 the result regarding lack of economic benefit is not surprising. Overall, evidence from two studies suggests that OSA treatments are associated with fewer days missed from work. 24, 30 In the broader sleep medicine literature, it is welldocumented that OSA treatments are associated with reduced accident risk (eg, MVC). [48] [49] [50] However, in the present review, no study found a beneficial effect from OSA treatment on monetized accident risk. These null findings can likely be attributed to the low frequency of chestjournal.org this outcome in the included studies and to our inclusion criteria requiring outcomes to be expressed in monetary units. Additional empirical studies are clearly needed to understand the economic impact of OSA treatments from a societal perspective, which includes all direct and indirect costs, including accidents.
Through this review, results suggest that costeffectiveness is closely linked to clinical effectiveness of OSA treatment. It is thus perhaps not surprising that the economic benefit of PAP related directly to PAP adherence. Although PAP is highly effective, many patients struggle to acclimate to the therapy, resulting in suboptimal long-term adherence that is comparable with adherence to medication therapies in other chronic diseases. 51 Of studies that evaluated the economic impact of PAP adherence, a clear majority (four of five) found PAP adherence to be associated positively with enhanced economic outcomes. 22, 27, 30, 37 Thus, the present results support maximizing PAP adherence as a clinical, public health, and economic imperative.
Cost-effectiveness is also strongly related to costs. Direct medical costs associated with OSA typically include outpatient encounters (ie, generalist or specialist consultation), diagnostic testing (ie, PSG or HSAT), treatment initiation and equipment (ie, in-laboratory or at-home PAP titration, OA titration, surgery, and so on), and ongoing medical oversight and supplies (ie, outpatient encounters, PAP mask, tubing, and filter resupply, replacement OAs, and so on). These costs typically decrease over time. To guide economic decision-making, one must weigh initial costs against the costs of untreated OSA, including increased HCU, diminished workplace productivity, increased disability rates, and increased accident risk, which could be expected to increase over time.
In addition to costs, sleep apnea severity and time horizon are important determinants of health economic decision-making. 52 In the present review, costeffectiveness was greatest among patients with severe OSA. Furthermore, although follow-ups were highly variable, longer time horizons were associated with more favorable economic outcomes. Because OSA costs are higher at the time of diagnosis and initiation of therapy, it can take several years for these costs to be recouped via reduced HCU. Time horizon is arguably even more important when considering comorbid OSA. In these instances, OSA treatments might not be powerful enough to overcome rapidly the combined up-front costs of OSA treatment along with costs associated with other comorbid conditions. Thus, researchers must strive to define the optimal time horizon for evaluating the cost-effectiveness of OSA treatments, as well as to identify other key outcomes for evaluating OSA comorbid with other costly conditions. Finally, perspective is central to the time horizon required because broader perspectives (eg, societal perspectives) that include direct and indirect costs of untreated OSA will allow for recouping costs more quickly.
Limitations
Although this systematic review captures the current state of the science, a number of limitations must be noted. First, this review included only studies examining cost-effectiveness or impact on monetized health economic outcomes. Many studies in the literature examine nonmonetized outcomes closely related to costs and cost savings, such as physician encounters, hospital readmissions, and MVCs. Relatively fewer studies examine the impact of OSA treatment on workplace productivity and disability, another key health economic outcome and a central outcome from the employer perspective. Second, our analyses were limited to publications in the English language. A large number of germane abstracts were excluded, and several studies not in the English language were excluded. Some of these abstracts may be developed into peer-reviewed publications. Similarly, including publications not in the English language could provide much-needed insight into the cost-effectiveness of OSA treatments around the globe, where important data are lacking. Third, the current project did not consider the costs associated with OSA diagnosis, which are substantial. OSA diagnosis is increasingly linked to OSA treatment through OSA pathways reflecting more intensive levels of care (eg, attended diagnosis and PAP titration vs HSAT and autoadjusting PAP). Evaluation of care pathways will become increasingly important as sleep medicine payment models transition from volume to value and population health. 13 
Future Directions
Results of the current project suggest several important areas for future research (Table 6 ). First and most important, we strongly recommend that future OSA trials include measures of direct and indirect OSA costs. Second, sleep researchers should include both general and disease-specific measures of HrQOL in OSA trials to evaluate the cost-effectiveness of OSA treatments within commonly accepted thresholds (ie, $50,000 per QALY). Third, studies of the economic aspects of treating OSA should include diverse populations, especially women, older adults, and children; different ethnic and racial groups; people with varying levels of OSA; and people with high-cost comorbidities (eg, HF, COPD, type 2 diabetes mellitus, depression). 53 Fourth, future studies should examine the linear dose-response relationship between PAP use and cost-effectiveness. Fifth, greater insight is needed into the cost-effectiveness of interventions designed to increase PAP use in diverse populations. Sixth, greater insight into the employer perspective is essential because roughly one-half of OSA indirect costs are associated with lost workplace productivity (ie, absenteeism) and workplace accident and injury risk. Greater insight into the cost-benefit ratio of treating OSA is likely to be of particular interest to the increasing number of large (N > 1,000) self-insured employers. 54 Seventh, given that a great majority of extant data are from select developed nations, studies including a wider variety of health-care delivery systems are warranted. Finally, in light of the rapidly expanding number of alternate OSA treatment modalities, comparative effectiveness analyses between OSA treatments will empower stakeholders to make evidencebased decisions regarding allocation of scare health-care resources.
Conclusions
OSA is a common and costly condition, with welldocumented adverse impacts on HrQOL and economic outcomes. Total societal-level expenditures associated with OSA are estimated at $160 billion per year in the United States alone. 14 Results of this systematic review indicate not only that the great majority of evidence supports the cost-effectiveness of PAP therapy for the treatment of OSA but also that other OSA treatments might be cost-effective. Health-care costs, physician visits, and days missed from work were all reduced from use of CPAP. In the modern health-care climate, patients, payers, and policy makers are increasingly attuned to not only the health outcomes but also the economic aspects of medical care. Thus, in light of the increasing prevalence of OSA and the significant adverse health consequences associated with the disease, these results should encourage payers and policy makers to expand access to sleep medicine care. 
